Literature DB >> 22659734

Perspectives on cancer stem cells in osteosarcoma.

Upal Basu-Roy1, Claudio Basilico, Alka Mansukhani.   

Abstract

Osteosarcoma is an aggressive pediatric tumor of growing bones that, despite surgery and chemotherapy, is prone to relapse. These mesenchymal tumors are derived from progenitor cells in the osteoblast lineage that have accumulated mutations to escape cell cycle checkpoints leading to excessive proliferation and defects in their ability to differentiate appropriately into mature bone-forming osteoblasts. Like other malignant tumors, osteosarcoma is often heterogeneous, consisting of phenotypically distinct cells with features of different stages of differentiation. The cancer stem cell hypothesis posits that tumors are maintained by stem cells and it is the incomplete eradication of a refractory population of tumor-initiating stem cells that accounts for drug resistance and tumor relapse. In this review we present our current knowledge about the biology of osteosarcoma stem cells from mouse and human tumors, highlighting new insights and unresolved issues in the identification of this elusive population. We focus on factors and pathways that are implicated in maintaining such cells, and differences from paradigms of epithelial cancers. Targeting of the cancer stem cells in osteosarcoma is a promising avenue to explore to develop new therapies for this devastating childhood cancer.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Bone cancer; Cancer stem cell; FGF; Mesenchymal tumors; Osteosarcoma; Sox2; Tumor initiating cell; Wnt signaling

Mesh:

Year:  2012        PMID: 22659734      PMCID: PMC3552024          DOI: 10.1016/j.canlet.2012.05.028

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  106 in total

1.  Evidence for the osteosarcoma stem cell.

Authors:  C Parker Gibbs; Padraic P Levings; Steven C Ghivizzani
Journal:  Curr Orthop Pract       Date:  2011-07

2.  Suppression of induced pluripotent stem cell generation by the p53-p21 pathway.

Authors:  Hyenjong Hong; Kazutoshi Takahashi; Tomoko Ichisaka; Takashi Aoi; Osami Kanagawa; Masato Nakagawa; Keisuke Okita; Shinya Yamanaka
Journal:  Nature       Date:  2009-08-09       Impact factor: 49.962

3.  Eyes wide open: a critical review of sphere-formation as an assay for stem cells.

Authors:  Erika Pastrana; Violeta Silva-Vargas; Fiona Doetsch
Journal:  Cell Stem Cell       Date:  2011-05-06       Impact factor: 24.633

4.  Rb regulates fate choice and lineage commitment in vivo.

Authors:  Eliezer Calo; Jose A Quintero-Estades; Paul S Danielian; Simona Nedelcu; Seth D Berman; Jacqueline A Lees
Journal:  Nature       Date:  2010-08-04       Impact factor: 49.962

5.  Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2.

Authors:  Alexander B Mohseny; Karoly Szuhai; Salvatore Romeo; Emilie P Buddingh; Inge Briaire-de Bruijn; Daniëlle de Jong; Melissa van Pel; Anne-Marie Cleton-Jansen; Pancras C W Hogendoorn
Journal:  J Pathol       Date:  2009-11       Impact factor: 7.996

Review 6.  Fibroblast growth factor signaling in embryonic and cancer stem cells.

Authors:  Petr Dvorak; Dana Dvorakova; Ales Hampl
Journal:  FEBS Lett       Date:  2006-02-28       Impact factor: 4.124

Review 7.  Diagnosis and management of bone malignancy in adolescence.

Authors:  Jonathan S C Caudill; Carola A S Arndt
Journal:  Adolesc Med State Art Rev       Date:  2007-05

8.  Expression of an exogenous human Oct-4 promoter identifies tumor-initiating cells in osteosarcoma.

Authors:  Padraic P Levings; Sean V McGarry; Thomas P Currie; David M Nickerson; Steven McClellan; Steven C Ghivizzani; Dennis A Steindler; C Parker Gibbs
Journal:  Cancer Res       Date:  2009-07-07       Impact factor: 12.701

9.  Targeting the osteosarcoma cancer stem cell.

Authors:  Valerie A Siclari; Ling Qin
Journal:  J Orthop Surg Res       Date:  2010-10-27       Impact factor: 2.359

10.  Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling.

Authors:  Christopher J Lengner; Heather A Steinman; James Gagnon; Thomas W Smith; Janet E Henderson; Barbara E Kream; Gary S Stein; Jane B Lian; Stephen N Jones
Journal:  J Cell Biol       Date:  2006-03-13       Impact factor: 10.539

View more
  39 in total

1.  CANCER STEM CELLS IN OSTEOSARCOMA.

Authors:  Lindsay Bashur; Guang Zhou
Journal:  Case Orthop J       Date:  2013

2.  Sox2 antagonizes the Hippo pathway to maintain stemness in cancer cells.

Authors:  Upal Basu-Roy; N Sumru Bayin; Kirk Rattanakorn; Eugenia Han; Dimitris G Placantonakis; Alka Mansukhani; Claudio Basilico
Journal:  Nat Commun       Date:  2015-04-02       Impact factor: 14.919

Review 3.  Bone microenvironment signals in osteosarcoma development.

Authors:  Arantzazu Alfranca; Lucia Martinez-Cruzado; Juan Tornin; Ander Abarrategi; Teresa Amaral; Enrique de Alava; Pablo Menendez; Javier Garcia-Castro; Rene Rodriguez
Journal:  Cell Mol Life Sci       Date:  2015-05-03       Impact factor: 9.261

4.  MiR-26a inhibits stem cell-like phenotype and tumor growth of osteosarcoma by targeting Jagged1.

Authors:  J Lu; G Song; Q Tang; J Yin; C Zou; Z Zhao; X Xie; H Xu; G Huang; J Wang; D-F Lee; R Khokha; H Yang; J Shen
Journal:  Oncogene       Date:  2016-06-06       Impact factor: 9.867

5.  Association between expression of nuclear receptor co-activator 5 protein and prognosis in postoperative patients with osteosarcoma.

Authors:  Ya Wu; Jian Wu; Qi-Rong Dong; Nai-Zhou Guo
Journal:  Oncol Lett       Date:  2017-12-05       Impact factor: 2.967

6.  Regulatory mechanism of microRNA-128 in osteosarcoma tumorigenesis and evolution through targeting SASH1.

Authors:  Zi Li; Jiangdong Ni; Deye Song; Muliang Ding
Journal:  Oncol Lett       Date:  2018-03-30       Impact factor: 2.967

7.  Modeling the Tumor Microenvironment and Pathogenic Signaling in Bone Sarcoma.

Authors:  Eric R Molina; Letitia K Chim; Sergio Barrios; Joseph A Ludwig; Antonios G Mikos
Journal:  Tissue Eng Part B Rev       Date:  2020-02-14       Impact factor: 6.389

8.  MSX2 inhibits the growth and migration of osteosarcoma cells by repressing SOX2.

Authors:  Yue Wu; Yi Jin; Norio Yamamoto; Akihiko Takeuchi; Shinji Miwa; Hiroyuki Tsuchiya; Zhijun Yang
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

9.  Structural studies of UBXN2A and mortalin interaction and the putative role of silenced UBXN2A in preventing response to chemotherapy.

Authors:  Sanam Sane; Ammara Abdullah; Morgan E Nelson; Hongmin Wang; Subhash C Chauhan; Samuel S Newton; Khosrow Rezvani
Journal:  Cell Stress Chaperones       Date:  2015-12-04       Impact factor: 3.667

10.  Knockdown of FBXO39 inhibits proliferation and promotes apoptosis of human osteosarcoma U-2OS cells.

Authors:  Jianrong Zheng; Wei You; Chuanxi Zheng; Peng Wan; Jinquan Chen; Xiaochun Jiang; Zhixiang Zhu; Zhixiong Zhang; Anqi Gong; Wei Li; Jifeng Tan; Tao Ji; Wei Guo; Shiquan Zhang
Journal:  Oncol Lett       Date:  2018-06-01       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.